Genocea Biosciences, Inc. (NASDAQ:GNCA) is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, GNCA is expected to report 3Q20 loss of $ 0.24 per share
For the full year, analysts anticipate top line of $ 0.90 million, while looking forward to loss of $ 1.21 per share bottom line.
Stock Performance
Shares of Genocea Biosciences, Inc. traded up $ 0.01 or 0.44 percent on Wednesday, reaching $ 2.27 with volume of 252.70 thousand shares. Genocea Biosciences, Inc. has traded high as $ 2.27 and has cracked $ 2.12 on the downward trend
According to the previous trading day, closing price of $ 2.27, representing a 105.45 % increase from the 52 week low of $ 1.10 and a 60.7 % decrease over the 52 week high of $ 5.75.
The company has a market capital of $ 116.58 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Genocea Biosciences, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.genocea.com
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to recall a patients pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify neoantigens and antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase 1/2a clinical trial, designed to direct a patients immune system to attack tumor.
